Dr. Wirth on the LIBRETTO-531 Trial With Selpercatinib in RET+ Medullary Thyroid Cancer

Video

Lori J. Wirth, MD, discusses the phase 3 LIBRETTO-531 trial of selpercatinib in patients with RET-mutant medullary thyroid cancer. 

Lori J. Wirth, MD, associate professor of medicine, Harvard Medical School, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, discusses the phase 3 LIBRETTO-531 trial (NCT04211337) of selpercatinib (Retevmo) in patients with RET-mutant medullary thyroid cancer. 

The multicenter, randomized, open-label phase 3 trial is currently underway, Wirth says, and it is comparing the use of selpercatinib with physician’s choice of vandetanib (Caprelsa) or cabozantinib (Cabometyx) in those with progressive, advanced disease that is naïve to kinase inhibitors. In the trial, if patients who receive treatment with either vandetanib or cabozantinib experience disease progression, they have the opportunity to crossover to receive selpercatinib, Wirth explains.

The primary end point of LIBRETTO-531 is treatment failure-free survival, With adds. This trial might shed light on how to better sequence gene-specific therapy with a multikinase inhibitor in this patient population, Wirth concludes. 

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD